Yanan Zhu
Stock Analyst at Wells Fargo
(2.80)
# 1,685
Out of 5,152 analysts
82
Total ratings
36.84%
Success rate
0.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $12 → $15 | $13.83 | +8.46% | 8 | Mar 3, 2026 | |
| QURE uniQure | Downgrades: Equal-Weight | $60 → $15 | $9.45 | +58.73% | 6 | Mar 3, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $45 → $38 | $16.46 | +130.86% | 8 | Feb 27, 2026 | |
| ACLX Arcellx | Downgrades: Equal-Weight | $115 | $114.31 | +0.60% | 1 | Feb 23, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Overweight | $40 → $50 | $41.07 | +21.74% | 3 | Feb 20, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $8 → $11 | $4.44 | +147.75% | 4 | Jan 5, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $82 → $100 | $76.57 | +30.60% | 4 | Jan 5, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $7.30 | +173.97% | 9 | Oct 23, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $2.05 | +95.60% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $29.90 | +50.50% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $1.61 | +645.34% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $1.42 | +76.06% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.54 | +225.73% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $4.17 | +235.73% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $26.48 | +164.35% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $3.89 | +157.07% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $58.23 | +11.63% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $9.65 | +210.88% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.39 | +925.64% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $3.33 | +13,415.95% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $734.04 | -55.59% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $79 → $70 | $10.24 | +583.59% | 2 | Oct 29, 2020 |
Intellia Therapeutics
Mar 3, 2026
Maintains: Equal-Weight
Price Target: $12 → $15
Current: $13.83
Upside: +8.46%
uniQure
Mar 3, 2026
Downgrades: Equal-Weight
Price Target: $60 → $15
Current: $9.45
Upside: +58.73%
Sarepta Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $45 → $38
Current: $16.46
Upside: +130.86%
Arcellx
Feb 23, 2026
Downgrades: Equal-Weight
Price Target: $115
Current: $114.31
Upside: +0.60%
Spyre Therapeutics
Feb 20, 2026
Maintains: Overweight
Price Target: $40 → $50
Current: $41.07
Upside: +21.74%
Taysha Gene Therapies
Jan 5, 2026
Maintains: Overweight
Price Target: $8 → $11
Current: $4.44
Upside: +147.75%
Ionis Pharmaceuticals
Jan 5, 2026
Maintains: Overweight
Price Target: $82 → $100
Current: $76.57
Upside: +30.60%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $7.30
Upside: +173.97%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.05
Upside: +95.60%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $29.90
Upside: +50.50%
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.61
Upside: +645.34%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.42
Upside: +76.06%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.54
Upside: +225.73%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $4.17
Upside: +235.73%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $26.48
Upside: +164.35%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.89
Upside: +157.07%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $58.23
Upside: +11.63%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $9.65
Upside: +210.88%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.39
Upside: +925.64%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $3.33
Upside: +13,415.95%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $734.04
Upside: -55.59%
Oct 29, 2020
Maintains: Overweight
Price Target: $79 → $70
Current: $10.24
Upside: +583.59%